Use of Interleukin-2 and Macrophages to Treat Herpes Simplex Virus Infection in Neonatal Mice
- 1 June 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 157 (6) , 1187-1192
- https://doi.org/10.1093/infdis/157.6.1187
Abstract
We have developed a model of therapy for herpes simplex virus (HSV) infection in neonatal mice. Using a lower dose of virus (102 plaque-forming units administered intraperitoneally), we have been able to treat infected mice with syngeneic or allogeneic adult mouse macrophages in combination with three doses of human recombinant interleukin-2. Therapy resulted in a 42%–85% survival rate. Although production of antibody to HSV was associated with successful treatment, early administration of antibody did not improve survival.Keywords
This publication has 7 references indexed in Scilit:
- Defective production of anti-herpes simplex virus antibody by neonatal mice. Reconstitution with Ia+ macrophages and T helper lymphocytes from nonimmune adult syngeneic mice.The Journal of Immunology, 1986
- Ontogeny of Protection of Neonatal Mice from Lethal Herpes Simplex Virus Infection by Human Leukocytes, Antiviral Antibody, and Recombinant α-InterferonPediatric Research, 1984
- Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity.The Journal of Immunology, 1982
- Protection of newborn mice from a lethal herpes simplex virus infection by human interferon, antibody, and leukocytes.The Journal of Immunology, 1982
- Protection of neonatal mice against herpes simplex viral infection by human antibody and leukocytes from adult, but not neonatal humans.The Journal of Immunology, 1981
- Vidarabine Therapy of Neonatal Herpes Simplex Virus InfectionPediatrics, 1980
- Specific lethality of silica for human peripheral blood mononuclear phagocytes, in vitroJournal of Immunological Methods, 1978